Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N D James

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2026
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Fizazi, G Attard, A A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 6, 2026
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate CancerC T A Parker, H-C Huang, E Grist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015S Gillessen, A Omlin, G Attard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trialN W Clarke, A Ali, F C Ingleby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2016
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015S Gillessen, A Omlin, G Attard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003N W Clarke, A Ali, F C Ingleby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2024
Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)C C Parker, P M Petersen, A D Cook, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2026
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upK Fizazi, G Attard, A A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 6, 2026
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate CancerC T A Parker, H-C Huang, E Grist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015S Gillessen, A Omlin, G Attard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trialN W Clarke, A Ali, F C Ingleby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2016
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015S Gillessen, A Omlin, G Attard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003N W Clarke, A Ali, F C Ingleby, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2024
Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)C C Parker, P M Petersen, A D Cook, et al.
Pageof 6